A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Tofacitinib (Primary) ; Methotrexate
- Indications Psoriatic arthritis
- Focus Adverse reactions; Registrational
- Acronyms OPAL BALANCE
- Sponsors Pfizer
- 05 Jul 2019 Status changed from active, no longer recruiting to completed.
- 05 Jul 2019 This trial is completed in Germany according to European Clinical Trials Database.
- 21 Jun 2019 This trial is completed in Spain and slovakia according to European Clinical Trials Database.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History